Title |
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2013
|
DOI | 10.1002/14651858.cd010482.pub2 |
Pubmed ID | |
Authors |
Theresa A Lawrie, Roy Rabbie, Clemens Thoma, Jo Morrison |
Abstract |
Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management. Currently, the recommended standard first-line chemotherapy is platinum-based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non-modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression-free survival compared with PAC/carbo in women with relapsed, platinum-sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first-line setting. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Canada | 1 | <1% |
Unknown | 136 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 20 | 14% |
Student > Ph. D. Student | 15 | 11% |
Researcher | 15 | 11% |
Student > Master | 12 | 9% |
Other | 11 | 8% |
Other | 19 | 14% |
Unknown | 46 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 48 | 35% |
Nursing and Health Professions | 12 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
Biochemistry, Genetics and Molecular Biology | 5 | 4% |
Psychology | 5 | 4% |
Other | 10 | 7% |
Unknown | 51 | 37% |